Daratumumab, Bortezomib, and Dexamethasone for Treatment of Patients with Relapsed or Refractory Multiple Myeloma and Severe Renal Impairment: Results from the Phase 2 GMMG-DANTE Trial

DSpace Repository

Daratumumab, Bortezomib, and Dexamethasone for Treatment of Patients with Relapsed or Refractory Multiple Myeloma and Severe Renal Impairment: Results from the Phase 2 GMMG-DANTE Trial

Author: Leypoldt, Lisa B.; Gavriatopoulou, Maria; Besemer, Britta; Salwender, Hans; Raab, Marc S.; Nogai, Axel; Khandanpour, Cyrus; Runde, Volker; Jauch, Anna; Zago, Manola; Martus, Peter; Goldschmidt, Hartmut; Bokemeyer, Carsten; Dimopoulos, Meletios A.; Weisel, Katja C.
Tübinger Autor(en):
Besemer, Britta
Zago, Manola
Martus, Peter
Published in: Cancers (2023), Bd. 15 (18), Article 4667
Verlagsangabe: Basel : Mdpi
Language: English
Full text: http://dx.doi.org/10.3390/cancers15184667
ISSN: 2072-6694
DDC Classifikation: 610 - Medicine and health
Dokumentart: Article
Show full item record

This item appears in the following Collection(s)